This Article Full Text Full Text (PDF) All Versions of this Article: 94/4/550    most recent 01.RES.0000117772.86853.34v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tran, P.-K. Articles by Hedin, U. Search for Related Content PubMed PubMed Citation Articles by Tran, P.-K. Articles by Hedin, U. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Substance via MeSH Related Collections Restenosis Genetically altered mice Smooth muscle proliferation and differentiation Coagulation Mechanism of atherosclerosis/growth factors

(Circulation Research. 2004;94:550.)
© 2004 American Heart Association, Inc.

Integrative Physiology

Increased Intimal Hyperplasia and Smooth Muscle Cell Proliferation in Transgenic Mice With Heparan Sulfate–Deficient Perlecan

Phan-Kiet Tran, Karin Tran-Lundmark, Raija Soininen, Karl Tryggvason, Johan Thyberg^*, Ulf Hedin^*

From the Department of Surgical Sciences (P.-K.T., K.T.-L., U.H.), Karolinska Hospital, and Departments of Medical Biochemistry and Biophysics (R.S., K.T.) and Cell and Molecular Biology (J.T.), Karolinska Institutet, Stockholm, Sweden.

Correspondence to Phan-Kiet Tran, Department of Surgical Sciences, Karolinska Hospital, SE-17176 Stockholm, Sweden. E-mail kiet.tran{at}kirurgi.ki.se

Smooth muscle cell (SMC) proliferation is a critical process in vascular disease. Heparan sulfate (HS) proteoglycans inhibit SMC growth, but the role of endogenous counterparts in the vessel wall in control of SMC function is not known in detail. Perlecan is the major HS proteoglycans in SMC basement membranes and in vessel wall extracellular matrix (ECM). In this study, transgenic mice with HS-deficient perlecan were analyzed with respect to vascular phenotype and intimal lesion formation. Furthermore, SMC cultures were established and characterized with respect to morphology, immunocytochemical features, proteoglycan synthesis, proliferative capacity, and ECM binding of basic fibroblast growth factor (FGF-2). In vitro, mutant SMCs formed basement membranes with perlecan core protein, but with decreased levels of HS, they showed diminished secretion of HS-containing perlecan into the medium and a defective ECM-binding capacity of FGF-2. In vitro, mutant SMCs showed increased proliferation compared with wild-type cells, and in vivo, enhanced SMC proliferation and intimal hyperplasia were observed after flow cessation of the carotid artery in mutant mice. The results indicate that the endogenous HS side-chains of perlecan contribute to SMC growth control both in vitro and during intimal hyperplasia, possibly by sequestering heparin-binding mitogens such as FGF-2.

Key Words: smooth muscle cells • perlecan • heparan sulfate proteoglycans • intimal hyperplasia • cell proliferation

This article has been cited by other articles:

				N. Fukai, R. D. Kenagy, L. Chen, L. Gao, G. Daum, and A. W. Clowes Syndecan-1: An Inhibitor of Arterial Smooth Muscle Cell Growth and Intimal Hyperplasia Arterioscler Thromb Vasc Biol, September 1, 2009; 29(9): 1356 - 1362. [Abstract] [Full Text] [PDF]

				K. Tran-Lundmark, P.-K. Tran, G. Paulsson-Berne, V. Friden, R. Soininen, K. Tryggvason, T. N. Wight, M. G. Kinsella, J. Boren, and U. Hedin Heparan Sulfate in Perlecan Promotes Mouse Atherosclerosis: Roles in Lipid Permeability, Lipid Retention, and Smooth Muscle Cell Proliferation Circ. Res., July 3, 2008; 103(1): 43 - 52. [Abstract] [Full Text] [PDF]

				Y. Nakashima, T. N. Wight, and K. Sueishi Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans Cardiovasc Res, July 1, 2008; 79(1): 14 - 23. [Abstract] [Full Text] [PDF]

				J. J. Zoeller, A. McQuillan, J. Whitelock, S.-Y. Ho, and R. V. Iozzo A central function for perlecan in skeletal muscle and cardiovascular development J. Cell Biol., April 21, 2008; 181(2): 381 - 394. [Abstract] [Full Text] [PDF]

				A. Kadenhe-Chiweshe, J. Papa, K. W. McCrudden, J. Frischer, J.-O Bae, J. Huang, J. Fisher, J. H. Lefkowitch, N. Feirt, J. Rudge, et al. Sustained VEGF Blockade Results in Microenvironmental Sequestration of VEGF by Tumors and Persistent VEGF Receptor-2 Activation Mol. Cancer Res., January 1, 2008; 6(1): 1 - 9. [Abstract] [Full Text] [PDF]

				H. Morita, A. Yoshimura, K. Inui, T. Ideura, H. Watanabe, L. Wang, R. Soininen, and K. Tryggvason Heparan Sulfate of Perlecan Is Involved in Glomerular Filtration J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1703 - 1710. [Abstract] [Full Text] [PDF]

				A. Segev, N. Nili, and B. H Strauss The role of perlecan in arterial injury and angiogenesis Cardiovasc Res, September 1, 2004; 63(4): 603 - 610. [Abstract] [Full Text] [PDF]

				Z. Zhou, J. Wang, R. Cao, H. Morita, R. Soininen, K. M. Chan, B. Liu, Y. Cao, and K. Tryggvason Impaired Angiogenesis, Delayed Wound Healing and Retarded Tumor Growth in Perlecan Heparan Sulfate-Deficient Mice Cancer Res., July 15, 2004; 64(14): 4699 - 4702. [Abstract] [Full Text] [PDF]